News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

MDX Medical Reports Addition of Investor Relations Director (CCN Newswire)...improving the safety and accuracy of radio-surgery for patients with brain tumors....- Jun 13 12:31 PM ET

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 06/13/2001

"Yahoo - MDX Medical Reports Addition of Investor Relations Director"
Yahoo! Finance Finance Home - Yahoo! - Help
Canadian Corp News

[ Latest Headlines | Market Overview | News Alerts ]

Related Quotes
delayed 20 mins - disclaimer
Wednesday June 13, 12:31 pm Eastern Time

Press Release

MDX Medical Reports Addition of Investor Relations Director

VANCOUVER, BRITISH COLUMBIA--MDX Medical Inc. (CDNX: MDK) is pleased to announce the appointment of Ms. Rupinder Bagri as Director of Investor Relations. Ms. Bagri holds a B.Sc. Degree and two years experience conducting investor relations in the biotech industry. Ms. Bagri will be carrying out all aspects of investor relations and corporate communications for MDX Medical.

MDX Medical is also pleased to report that its Annual General Meeting was held on June 12, 2001 at which time existing directors, Paul K. Conibear, K. Alan Blair, and Dr. Brian Lentle were re-elected for the ensuing year.

About MDX

MDX Medical is focused on the development and commercialization of medical device technologies emanating from universities, hospitals, and other research institutions. The Company's strategy is to develop non-invasive medical device technologies with large market or high profit niche market potential. These technologies will be complementary to its core expertise in sensor technology, signal and image processing and advanced electronics.

MDX Medical is currently developing the AE Osteoporosis and Film Phantom Technologies. The AE Osteoporosis Technology is targeted to be a low cost measurement device with diagnostic software that assists in detection and monitoring of osteoporosis. The AE Osteoporosis technology was acquired through an exclusive license from the University of British Columbia. The Film Phantom Technology is a simulation device and software developed by and licensed from the BC Cancer Agency to provide a practical and cost-effective approach to improving the safety and accuracy of radio-surgery for patients with brain tumors.

On behalf of the Board,

Alan Blair, Director

MDX Medical Inc.
Ms. Rupinder Bagri, B.Sc.
Director, Investor Relations
(604) 875-4529
(604) 875-5390

Email this story - Most-emailed articles - Most-viewed articles

More Quotes and News:MDX Medical Inc (Vancouver:MDK.V - news)
Related News Categories: medical/pharmaceutical


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Canadian Corp News. CCN Newswire All rights reserved. All news releases provided by CCN Newswire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557